Neoadjuvant imatinib for unresectable gastrointestinal stromal tumor.
We have evaluated the feasibility of the use of neoadjuvant imatinib mesylate in the management of unresectable localized gastrointestinal stromal tumors. In a pilot experience, two patients with unresectable gastrointestinal tumors were treated with neoadjuvant imatinib. Their treatment course and surgical outcomes are described. In both cases, the patient attained sufficient tumor regression to enable complete resection of tumor. We conclude that in the management of unresectable gastrointestinal stromal tumors, neoadjuvant administration of imatinib may facilitate sufficient tumor regression to facilitate subsequent tumor resection with curative intent.
Katz
Daniela
D
Shaare Zedek Medical Center, Jerusalem, Israel.
Segal
Amiel
A
Alberton
Yossef
Y
Jurim
Oded
O
Reissman
Petachia
P
Catane
Raphael
R
Cherny
Nathan I
NI
D001549:Benzamides; D001706:Biopsy; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D004334:Drug Administration Schedule; D005500:Follow-Up Studies; D005743:Gastrectomy; D005770:Gastrointestinal Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D000068877:Imatinib Mesylate; D007417:Intestinal Polyps / Q000175:diagnosis / Q000473:pathology; D007557:Israel; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy / Q000379:methods*; D009361:Neoplasm Invasiveness / Q000000981:diagnostic imaging; D010879:Piperazines / Q000008:administration & dosage / Q000627:therapeutic use*; D011184:Postoperative Period; D011743:Pyrimidines / Q000008:administration & dosage / Q000627:therapeutic use*; D012074:Remission Induction / Q000379:methods; D013156:Splenectomy; D017154:Stromal Cells / Q000187:drug effects* / Q000473:pathology; D036542:Tomography, Spiral Computed; D016896:Treatment Outcome
D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate